Protagonist Therapeutics Newsroom

Protagonist Therapeutics Reports Granting of Inducement Awards

AccesswireJan 7 05:05

Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025

AccesswireDec 20, 2024 05:05

Clear Street Launches Healthcare & Biotechnology Equity Research

BusinesswireDec 18, 2024 03:00

BTIG Upgrades Protagonist Therapeutics(PTGX.US) to Buy Rating, Maintains Target Price $67

Futu NewsDec 11, 2024 02:32 · Ratings

JMP Securities Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $58

Futu NewsDec 11, 2024 01:32 · Ratings

Optimistic Buy Rating for Protagonist Therapeutics Driven by Promising Rusfertide Data and Strategic Takeda Partnership

TipRanksDec 11, 2024 01:05 · Ratings

H.C. Wainwright Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $50

Futu NewsDec 10, 2024 20:31 · Ratings

J.P. Morgan Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating

Futu NewsDec 10, 2024 20:31 · Ratings

Analysts Are Bullish on Top Healthcare Stocks: AbbVie (ABBV), Protagonist Therapeutics (PTGX)

TipRanksDec 10, 2024 19:40 · Ratings

Protagonist Reports Final Results From Rusfertide Phase 2 REVIVE Study Showing Durable Hematocrit Control at the ASH 2024 Annual Meeting

AccesswireDec 10, 2024 05:05

Protagonist Therapeutics Initiated at Outperform by BMO Capital

Dow JonesDec 6, 2024 19:26 · Ratings

Protagonist Therapeutics Analyst Ratings

BenzingaDec 6, 2024 19:14 · Ratings

Goldman Sachs Initiates Protagonist Therapeutics(PTGX.US) With Hold Rating, Announces Target Price $47

Futu NewsDec 6, 2024 06:31 · Ratings

BMO Capital Initiates Protagonist Therapeutics(PTGX.US) With Buy Rating, Announces Target Price $62

Futu NewsDec 6, 2024 05:31 · Ratings

Buy Rating Affirmed for Protagonist Therapeutics: Innovative Peptide Platform and Promising Pipeline Drive Growth Prospects

TipRanksDec 6, 2024 05:25 · Ratings

JMP Securities Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $58

Futu NewsDec 6, 2024 01:35 · Ratings

Yun Zhong, PhD, Joins Wedbush Securities as Senior Vice President, Equity Research, Biotechnology

BusinesswireDec 3, 2024 21:30

Is Weakness In Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock A Sign That The Market Could Be Wrong Given Its Strong Financial Prospects?

Yahoo FinanceNov 29, 2024 20:05

Protagonist Therapeutics Insider Sold Shares Worth $1,414,402, According to a Recent SEC Filing

MT NewswiresNov 29, 2024 16:29

Protagonist Therapeutics(PTGX.US) Officer Sells US$5.64 Million in Common Stock

$Protagonist Therapeutics(PTGX.US)$ Officer Gupta Suneel sold 122.63K shares of common stock on Nov 25, 26, 2024 at an average price of $45.96 for a total value of $5.64 million.Source: Announcement

Futu NewsNov 28, 2024 08:14